In the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), researchers found that liraglutide reduced the risk of cardiovascular events in diabetic patients, including heart attack, stroke, and cardiovascular death, by 13% compared to placebo
Start with a 0.5-1% concentration serum applied once daily to a clean, dry scalp in the area(s) where youre experiencing thinning
What If I'm Already Using a GLP-1 Medication Can I Add BPC-157 and TB-500
(KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a licensing and collaboration agreement to discover, develop and commercialize siRNA therapeutics in key targeted indications in Greater China, which includes mainland China, Taiwan, Hong Kong and Macau
GLP-1s offer new revenue opportunities for digital health players It's not hard to see why digital health companies are going all-in on the GLP-1 boom